PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Net income growth similar to TRVN's 17.09%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
4.17%
Some D&A expansion while TRVN is negative at -0.92%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Negative yoy deferred tax while TRVN stands at 78.57%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-2.08%
Negative yoy SBC while TRVN is 32.26%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-115.45%
Both reduce yoy usage, with TRVN at -247.39%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Both negative yoy AP, with TRVN at -190.09%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-68.80%
Negative yoy usage while TRVN is 102110.64%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
119.47%
Well above TRVN's 3.19%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
9.84%
Some CFO growth while TRVN is negative at -96.26%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth well above TRVN's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
We have mild expansions while TRVN is negative at -1440.74%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
64.41%
Debt repayment growth of 64.41% while TRVN is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Both yoy lines negative, with TRVN at -41.55%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.